Mylan Revenue 2006-2018 | MYL

Current and historical revenue for Mylan (MYL) from 2006 to 2018. Revenue can be defined as the sum of all revenue fields included for a company's operating activities. Mylan revenue for the twelve months ending June 30, 2018 was $11.719B. Mylan revenue for the three months ending June 30, 2018 was $2.808B, representing a 5.2% decline from the same quarter last year.
Mylan Annual Revenue
(Millions of US $)
2017 $11,908
2016 $11,077
2015 $9,429
2014 $7,720
2013 $6,909
2012 $6,796
2011 $6,130
2010 $5,451
2009 $5,093
2008 $5,138
2007 $2,179
2007 $1,612
2006 $1,257
2005 $1,253
Mylan Quarterly Revenue
(Millions of US $)
Q2 2018 $2,808
Q1 2018 $2,685
Q4 2017 $3,239
Q3 2017 $2,987
Q2 2017 $2,962
Q1 2017 $2,720
Q4 2016 $3,268
Q3 2016 $3,057
Q2 2016 $2,561
Q1 2016 $2,191
Q4 2015 $2,491
Q3 2015 $2,695
Q2 2015 $2,372
Q1 2015 $1,872
Q4 2014 $2,083
Q3 2014 $2,084
Q2 2014 $1,837
Q1 2014 $1,716
Q4 2013 $1,809
Q3 2013 $1,767
Q2 2013 $1,702
Q1 2013 $1,632
Q4 2012 $1,723
Q3 2012 $1,802
Q2 2012 $1,688
Q1 2012 $1,584
Q4 2011 $1,531
Q3 2011 $1,576
Q2 2011 $1,574
Q1 2011 $1,449
Q4 2010 $1,434
Q3 2010 $1,355
Q2 2010 $1,369
Q1 2010 $1,292
Q4 2009 $1,352
Q3 2009 $1,264
Q2 2009 $1,267
Q1 2009 $1,210
Q4 2008 $1,203
Q3 2008 $1,657
Q2 2008 $1,203
Q1 2008 $1,074
Q4 2007 $668
Q3 2007 $477
Q2 2007 $546
Q1 2007 $487
Q4 2006 $402
Q3 2006 $367
Q2 2006 $356
Q1 2006 $0
Q4 2005 $311
Q3 2005 $298
Q2 2005 $323
Q1 2005 $0
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $19.669B $11.908B
Mylan NV is a pharmaceutical company. The company develops, licenses, manufactures, markets and distributes generic and specialty pharmaceuticals. It operates primarily in the United States, Canada, Europe, the Middle East, Africa, India, Australia, Japan and New Zealand. Mylan NV, formerly known as Mylan Inc., is based in Canonsburg, Pennsylvania.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $63.001B 10.81
Teva Pharmaceutical Industries (TEVA) Israel $24.629B 6.88
Bausch Health Cos (BHC) Canada $7.633B 5.70
Dr Reddy's Laboratories (RDY) India $5.610B 25.06
Mallinckrodt Public (MNK) United Kingdom $2.887B 4.91
Akorn (AKRX) United States $2.382B 0.00
Supernus Pharmaceuticals (SUPN) United States $2.339B 25.03
Assembly Biosciences (ASMB) United States $0.930B 0.00
Amphastar Pharmaceuticals (AMPH) United States $0.824B 118.80
CymaBay Therapeutics (CBAY) United States $0.723B 0.00
Voyager Therapeutics (VYGR) United States $0.626B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.610B 0.00
Homology Medicines (FIXX) United States $0.607B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.589B 0.00
Corium (CORI) United States $0.324B 0.00
Teligent (TLGT) United States $0.228B 0.00
Sol-Gel Technologies (SLGL) Israel $0.119B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.111B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.071B 0.00
Aevi Genomic Medicine (GNMX) United States $0.069B 0.00
Versartis (VSAR) United States $0.065B 0.00
Evoke Pharma (EVOK) United States $0.041B 0.00
Pernix Therapeutics Holdings (PTX) United States $0.020B 0.00
Acasti Pharma (ACST) Canada $0.017B 0.00
Agile Therapeutics (AGRX) United States $0.009B 0.00